Week 16, 2018pdf, World Health Organization, SouthEast Asia Regional Office
Vol. 22, Week 16, 2018
Published 23 April 2018
Meetings/ Important events:
Ninth meeting of SEAR Immunization Technical Advisory Group (SEAR-ITAG), New Delhi, 17 to 20 July 2018
Third Meeting of the South-East Asia Regional Verification Commission for Measles Elimination and Rubella/ CRS Control (SEA-RVC),
Kathmandu, Nepal, 31 July to 2 August 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 23 April 2018)
Case classification (number)
Epidemiologicallyconfirmed
Discarded non-measles nonrubella cases
Pending classification
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na tiona l
ca s es per
l evel per
n
100,000
pop
100,000 pop n
Laboratory-confirmed
Rubel l a
Clinically-compatible
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
s erum
mea s l es
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
1,141
95
96
1,091
100
91
89
325
12
10
40
2
646
106
1.27
19
6.82
Bhutan
48
98
100
47
62
98
66
9*
0
0
1
0
38
0
15.63
50
37.02
4.11
DPR Korea
0
0
0
0
0
0
0
0
0
0
0
0.00
ND
0.00
0.00
0.29
Countries
Bangladesh
India 3
Indonesia
4
Maldives
Myanmar
Nepal
0.83
9,153
0
33
2,720
83
52
32
983
26
0
123
0
270
7,751
0.06
1
2.41
656
0
100
655
98
95
90
133
0
1
193
0
293
36
0.36
4
1.64
2.37
8
38
88
7
71
100
57
0
0
0
0
0
7
1
6.72
15
0.00
0.00
53
87
53
28
86
100
96
27
0
0
0
0
19
7
0.12
2
1.68
0.00
289
99
96
175
76
91
0
13
0
5
5
0
149
117
1.67
23
2.02
0.56
0.42
Sri Lanka
37
89
81
28
89
100
64
1
0
2
0
0
32
2
0.48
4
62.00
Thailand
755
34
89
632
74
97
53
288
4
160
9
0
275
19
1.37
ND
22.60
0.45
58
97
97
56
102
88
86
0
0
0
2
0
48
8
12.07
23
0.00
5.03
12,198
15
49
5,439
87
73
53
1,779
42
178
373
2
1,777
8,047
0.09
3.28
0.61
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
* Impo rted cases
A lso includes the cases fro m enhanced measles case-based surveillance.
ND=No data
3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 23 April 2018)
Case classification (number)
India 3
Indonesia
4
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-compatible
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
s erum
mea s l es
on
ca s es
i ni tia ted s peci mens
col l ected
w/i n 48
hours of
notifi ca tion
8,025
94
81
6,467
100
100
64
2,612
982
407
240
59
3,725
0
2.28
58
24.54
1.83
439
91
90
263
79
100
38
30*
0
0
3
0
406
0
51.38
90
37.96
3.80
0.00
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.43
ND
0.00
21,391
0
31
6,493
95
87
59
3,268
7,693
0
747
2,112
2,866
4,705
0.21
3
8.19
2.14
13,215
0
99
13,032
97
99
36
4,636
0
6
4,320
0
4,082
171
1.56
16
17.72
16.50
Maldives
66
97
100
66
100
100
71
1*
0
0
1
0
64
0
18.91
60
2.95
2.95
Myanmar
1,785
40
90
1,610
99
100
93
1,032
208
77
6
0
462
0
0.88
15
25.21
0.11
Nepal
1,033
96
91
942
40
100
71
64
22
13
21
0
911
2
3.18
59
3.46
0.73
Sri Lanka
242
98
89
212
92
100
64
1
0
22
2
0
217
0
1.03
19
62.00
0.42
Thailand
2,979
28
85
2,418
59
95
60
1,467
9
579
24
0
806
94
1.23
ND
31.26
0.37
134
100
99
133
100
99
67
0
0
0
5
0
129
0
9.98
38
0.00
3.87
49,414
22
65
31,741
93
97
53
13,111
8,914
1,104
5,369
2,171
13,773
4,972
0.70
11.81
3.85
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
* Impo rted cases
A lso includes the cases fro m enhanced measles case-based surveillance.
ND=No data
3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
http://www.searo.who.int/topics/immunization/
Vol. 22,
Week 16, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 23 April 2018)
2017 (Onset)
2018 (Onset)
AFP
Surveillance Indicators
1
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
AFP Cases
Wild Poliovirus Cases
Vaccine Derived
Poliovirus Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
0
0
0
1 347
16
16
2.74
2.70
98
99
363
0
0
0
239
124
1
2.39
1.57
99
99
9
0
0
0
8
1
1
3.64
3.24
89
100
1
0
0
0
0
1
0
1.31
0.00
100
100
104
0
0
0
91
13
11
1.82
1.59
97
100
0
0
0
0
0
0
0
0.00
0.00
0
0
India
39 339
0
0
23
38 535
781
781
8.97
8.79
86
98
8 512
0
0
0
194
6.31
4.98
87
98
Indonesia
1 689
0
0
2
1 557
130
130
2.40
2.21
82
97
292
0
0
0
204
88
12
1.35
0.94
82
97
Maldives
7
0
0
0
6
1
1
7.40
6.34
71
100
3
0
0
0
0
3
0
10.31
0.00
67
67
Myanm ar
396
0
0
0
391
5
5
2.94
2.90
95
100
45
0
0
0
39
6
1
1.08
0.94
96
100
Nepal
371
0
0
0
369
2
2
4.28
4.25
98
100
94
0
0
0
67
27
0
3.52
2.51
95
100
Sri Lanka
70
0
0
0
69
1
1
1.29
1.27
84
100
16
0
0
0
14
2
0
0.96
0.84
69
94
Thailand
198
0
0
0
179
19
19
1.71
1.55
68
95
15
0
0
0
0
15
4
0.42
0.00
87
100
0
0
0
0.00
0.00
0
0
212
5.03
3.92
87
98
Bangladesh
Bhutan
DPR Korea
Tim or-Leste
SEAR
Pending
3
0
0
0
1
2
1
0.65
0.22
33
100
0
0
0
0
43 549
0
0
25
42 553
971
968
7.21
7.04
86
98
9 341
0
0
0
Pending
6 713 1 799
7 276 2 065
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
% with any specimen
AFP Rate
1 363
Country
% with 2 spec., at least
24 hrs apart, w/in 14
days
>90 Days 3
Specim en
Total
1
Discarded (Non-polio
AFP)
Case Classification
Compatible
Specim en
Vaccine Derived
Poliovirus Cases
2
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 23 April 2018)
0
0
7
5
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
3
Vaccine
mixture
NPEV by
PCR
0
0
0
0
0
0
>7
days
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
231
0
78
0
0
0
0
65
79
9
0
0
0
0
111
0
25
0
0
0
0
30
54
1
0
0
1
0
NIV, Bengaluru
151
0
58
0
0
0
0
33
45
15
0
0
0
0
63
0
13
0
0
0
0
22
25
2
0
0
0
1
ERC, Mumbai
159
0
51
0
0
0
0
48
39
21
0
0
0
0
69
0
16
0
0
0
0
29
23
1
0
0
0
0
SGPGI, Lucknow
288
0
59
0
0
0
0
99
64
25
41
0
0
0
110
0
31
0
0
0
0
40
36
1
0
0
2
0
KIPM, Chennai
50
0
10
0
0
0
0
26
14
0
0
0
0
0
47
0
13
0
0
0
0
16
18
0
0
0
0
0
NCDC, Delhi
202
0
56
0
0
0
0
88
50
8
0
0
0
0
89
0
29
0
0
0
0
31
29
0
0
0
0
0
IoS, Kolkatta
175
0
55
0
0
0
0
41
57
19
3
0
0
0
82
0
23
0
0
0
0
23
32
1
1
0
2
0
CRI, Kasauli
22
0
11
0
0
0
0
6
5
0
0
0
0
0
14
0
3
0
0
0
0
3
7
0
0
0
0
1
1 278
0
378
0
0
0
0
406
353
97
44
0
0
0
585
0
153
0
0
0
0
194
224
6
1
0
5
2
2
0
0
0
0
0
0
2
0
0
0
0
0
0
0
Bio Farma, Bandung
NIHRD, Jakarta
3
0
1
0
0
0
0
0
2
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
2
PHL, Surabaya
1
0
0
0
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
2
0
153
0
0
0
0
197
226
6
1
0
5
4
Indonesia Total
6
0
1
0
0
0
0
3
2
0
0
0
0
0
4
Myanm ar
NHL, Yangon
6
0
1
0
0
0
0
4
1
0
0
0
0
0
0
Nepal
NIH, Bangkok
5
0
0
0
0
0
0
3
2
0
0
0
0
0
0
Sri Lanka
MRI, Colombo
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
5
0
2
0
0
0
0
3
0
0
0
0
0
0
0
1 320
0
390
0
0
0
0
426
363
97
44
0
0
0
592
TOTAL
0
Published 23 April 2018
Meetings/ Important events:
Ninth meeting of SEAR Immunization Technical Advisory Group (SEAR-ITAG), New Delhi, 17 to 20 July 2018
Third Meeting of the South-East Asia Regional Verification Commission for Measles Elimination and Rubella/ CRS Control (SEA-RVC),
Kathmandu, Nepal, 31 July to 2 August 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 23 April 2018)
Case classification (number)
Epidemiologicallyconfirmed
Discarded non-measles nonrubella cases
Pending classification
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
non-rubel l a
pop n
pop n
na tiona l
ca s es per
l evel per
n
100,000
pop
100,000 pop n
Laboratory-confirmed
Rubel l a
Clinically-compatible
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
s erum
mea s l es
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
1,141
95
96
1,091
100
91
89
325
12
10
40
2
646
106
1.27
19
6.82
Bhutan
48
98
100
47
62
98
66
9*
0
0
1
0
38
0
15.63
50
37.02
4.11
DPR Korea
0
0
0
0
0
0
0
0
0
0
0
0.00
ND
0.00
0.00
0.29
Countries
Bangladesh
India 3
Indonesia
4
Maldives
Myanmar
Nepal
0.83
9,153
0
33
2,720
83
52
32
983
26
0
123
0
270
7,751
0.06
1
2.41
656
0
100
655
98
95
90
133
0
1
193
0
293
36
0.36
4
1.64
2.37
8
38
88
7
71
100
57
0
0
0
0
0
7
1
6.72
15
0.00
0.00
53
87
53
28
86
100
96
27
0
0
0
0
19
7
0.12
2
1.68
0.00
289
99
96
175
76
91
0
13
0
5
5
0
149
117
1.67
23
2.02
0.56
0.42
Sri Lanka
37
89
81
28
89
100
64
1
0
2
0
0
32
2
0.48
4
62.00
Thailand
755
34
89
632
74
97
53
288
4
160
9
0
275
19
1.37
ND
22.60
0.45
58
97
97
56
102
88
86
0
0
0
2
0
48
8
12.07
23
0.00
5.03
12,198
15
49
5,439
87
73
53
1,779
42
178
373
2
1,777
8,047
0.09
3.28
0.61
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
* Impo rted cases
A lso includes the cases fro m enhanced measles case-based surveillance.
ND=No data
3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 23 April 2018)
Case classification (number)
India 3
Indonesia
4
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
DPR Korea
Rubel l a
Clinically-compatible
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
s erum
mea s l es
on
ca s es
i ni tia ted s peci mens
col l ected
w/i n 48
hours of
notifi ca tion
8,025
94
81
6,467
100
100
64
2,612
982
407
240
59
3,725
0
2.28
58
24.54
1.83
439
91
90
263
79
100
38
30*
0
0
3
0
406
0
51.38
90
37.96
3.80
0.00
105
100
100
105
100
100
99
0
0
0
0
0
105
0
0.43
ND
0.00
21,391
0
31
6,493
95
87
59
3,268
7,693
0
747
2,112
2,866
4,705
0.21
3
8.19
2.14
13,215
0
99
13,032
97
99
36
4,636
0
6
4,320
0
4,082
171
1.56
16
17.72
16.50
Maldives
66
97
100
66
100
100
71
1*
0
0
1
0
64
0
18.91
60
2.95
2.95
Myanmar
1,785
40
90
1,610
99
100
93
1,032
208
77
6
0
462
0
0.88
15
25.21
0.11
Nepal
1,033
96
91
942
40
100
71
64
22
13
21
0
911
2
3.18
59
3.46
0.73
Sri Lanka
242
98
89
212
92
100
64
1
0
22
2
0
217
0
1.03
19
62.00
0.42
Thailand
2,979
28
85
2,418
59
95
60
1,467
9
579
24
0
806
94
1.23
ND
31.26
0.37
134
100
99
133
100
99
67
0
0
0
5
0
129
0
9.98
38
0.00
3.87
49,414
22
65
31,741
93
97
53
13,111
8,914
1,104
5,369
2,171
13,773
4,972
0.70
11.81
3.85
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
* Impo rted cases
A lso includes the cases fro m enhanced measles case-based surveillance.
ND=No data
3 Case based surveillance is in the pro cess o f expansio n to all o ver the co untry and thus may no t reflect a co mplete picture o f the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
http://www.searo.who.int/topics/immunization/
Vol. 22,
Week 16, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 23 April 2018)
2017 (Onset)
2018 (Onset)
AFP
Surveillance Indicators
1
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
AFP Cases
Wild Poliovirus Cases
Vaccine Derived
Poliovirus Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
0
0
0
1 347
16
16
2.74
2.70
98
99
363
0
0
0
239
124
1
2.39
1.57
99
99
9
0
0
0
8
1
1
3.64
3.24
89
100
1
0
0
0
0
1
0
1.31
0.00
100
100
104
0
0
0
91
13
11
1.82
1.59
97
100
0
0
0
0
0
0
0
0.00
0.00
0
0
India
39 339
0
0
23
38 535
781
781
8.97
8.79
86
98
8 512
0
0
0
194
6.31
4.98
87
98
Indonesia
1 689
0
0
2
1 557
130
130
2.40
2.21
82
97
292
0
0
0
204
88
12
1.35
0.94
82
97
Maldives
7
0
0
0
6
1
1
7.40
6.34
71
100
3
0
0
0
0
3
0
10.31
0.00
67
67
Myanm ar
396
0
0
0
391
5
5
2.94
2.90
95
100
45
0
0
0
39
6
1
1.08
0.94
96
100
Nepal
371
0
0
0
369
2
2
4.28
4.25
98
100
94
0
0
0
67
27
0
3.52
2.51
95
100
Sri Lanka
70
0
0
0
69
1
1
1.29
1.27
84
100
16
0
0
0
14
2
0
0.96
0.84
69
94
Thailand
198
0
0
0
179
19
19
1.71
1.55
68
95
15
0
0
0
0
15
4
0.42
0.00
87
100
0
0
0
0.00
0.00
0
0
212
5.03
3.92
87
98
Bangladesh
Bhutan
DPR Korea
Tim or-Leste
SEAR
Pending
3
0
0
0
1
2
1
0.65
0.22
33
100
0
0
0
0
43 549
0
0
25
42 553
971
968
7.21
7.04
86
98
9 341
0
0
0
Pending
6 713 1 799
7 276 2 065
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
% with any specimen
AFP Rate
1 363
Country
% with 2 spec., at least
24 hrs apart, w/in 14
days
>90 Days 3
Specim en
Total
1
Discarded (Non-polio
AFP)
Case Classification
Compatible
Specim en
Vaccine Derived
Poliovirus Cases
2
Wild Poliovirus Cases
AFP Rates
Surveillance Indicators
Annualized
AFP Rates 2
AFP Cases
Case Classification
AFP
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 23 April 2018)
0
0
7
5
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
3
Vaccine
mixture
NPEV by
PCR
0
0
0
0
0
0
>7
days
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
231
0
78
0
0
0
0
65
79
9
0
0
0
0
111
0
25
0
0
0
0
30
54
1
0
0
1
0
NIV, Bengaluru
151
0
58
0
0
0
0
33
45
15
0
0
0
0
63
0
13
0
0
0
0
22
25
2
0
0
0
1
ERC, Mumbai
159
0
51
0
0
0
0
48
39
21
0
0
0
0
69
0
16
0
0
0
0
29
23
1
0
0
0
0
SGPGI, Lucknow
288
0
59
0
0
0
0
99
64
25
41
0
0
0
110
0
31
0
0
0
0
40
36
1
0
0
2
0
KIPM, Chennai
50
0
10
0
0
0
0
26
14
0
0
0
0
0
47
0
13
0
0
0
0
16
18
0
0
0
0
0
NCDC, Delhi
202
0
56
0
0
0
0
88
50
8
0
0
0
0
89
0
29
0
0
0
0
31
29
0
0
0
0
0
IoS, Kolkatta
175
0
55
0
0
0
0
41
57
19
3
0
0
0
82
0
23
0
0
0
0
23
32
1
1
0
2
0
CRI, Kasauli
22
0
11
0
0
0
0
6
5
0
0
0
0
0
14
0
3
0
0
0
0
3
7
0
0
0
0
1
1 278
0
378
0
0
0
0
406
353
97
44
0
0
0
585
0
153
0
0
0
0
194
224
6
1
0
5
2
2
0
0
0
0
0
0
2
0
0
0
0
0
0
0
Bio Farma, Bandung
NIHRD, Jakarta
3
0
1
0
0
0
0
0
2
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
2
PHL, Surabaya
1
0
0
0
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
2
0
153
0
0
0
0
197
226
6
1
0
5
4
Indonesia Total
6
0
1
0
0
0
0
3
2
0
0
0
0
0
4
Myanm ar
NHL, Yangon
6
0
1
0
0
0
0
4
1
0
0
0
0
0
0
Nepal
NIH, Bangkok
5
0
0
0
0
0
0
3
2
0
0
0
0
0
0
Sri Lanka
MRI, Colombo
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
5
0
2
0
0
0
0
3
0
0
0
0
0
0
0
1 320
0
390
0
0
0
0
426
363
97
44
0
0
0
592
TOTAL
0